September 23.-24. 2022
Nephrology meets Haemato-Oncology
We cordially invite you to the 1st joint meeting organised by the Mayo Clinic and the Medical University of Innsbruck “Nephrology meets Haemato-Oncology”. In particular, our meeting will focus on the emerging field of “Nephro-Oncology” and intents to reflect state-of-the art treatments with an interdisciplinary scope.
This meeting will be a highlight with several, international well-renowned speakers and we are looking forward to welcoming you to this outstanding event at the ‘heart of the alps’, our beautiful city of Innsbruck.
The meeting will be held in the city centre and the meeting should be as interactive as possible. It is designed as an expert meeting with time to discuss and to network with the leading experts in nephrology and haemato-oncology from all over the world.
Innsbruck as the place of the meeting is located in the Austrian Alps and hosted two Winter Olympics (1964 and 1976) in the past. September is one of the most beautiful months in the capital of Tyrol.
We hope to welcome you in Innsbruck in September 2022.
Gabriele Gamerith & Andreas Kronbichler
Mayo Clinic, Rochester, MN, USA
Division of Nephrology and Hypertension
AC Hotel by Marriott Innsbruck
Salurner Str. 15, 6020 Innsbruck AT
We will claim 14 CME points from the Austrian Medical Chamber.
Professional Congress Organizer
Andreas-Hofer-Strasse 6 EG, 6020 Innsbruck, Austria
12:10 Renal histology in ANCA-associated vasculitis- Ingeborg Bajema
12:40 Pulmonary lesions in PR3-and MPO-ANCA vasculitis- Ulrich Specks
13:10 Beyond B-cell depletion in ANCA-associated vasculitis – new strategies ahead? – Benjamin Terrier
13:40 COFFEE BREAK
14:00 Drug-induced vasculitis – focus on anti-tumour agents- Augusto Vaglio
14:30 IgG4-related disease: the true “chameleon” in medicine- John Stone
15:00 COFFEE BREAK
15:30 Diagnosis of monoclonal gammopathy of renal significance / multiple myeloma- Mariam Priya Alexander
16:00 Management of MGRS in the year 2022- Ladan Zand
16:30 Inflammatory pathways in multiple myeloma: complement and beyond- Luis Quintana
17:00 MM and AL-Amyloidosis – treatment in patients with compromised renal function. Choice and sequencing of drugs in 2022- Stathis Kastritis
17:30 Come together & CONSENSUS PAPER Meeting
19:00 Conference DINNER
09:00 Donors with history of malignancy- Hatem Amer
09:30 Post-tranplant lymphoproliferative disorder (PTLD): Evidence-based treatment- Daan Dierickx
10:00 Cancer risk in the CKD/transplant population- Hatem Amer
11:00 Pathomechanisms leading to hypercoagulability- Henri Versteeg
11:30 Cancer-associated thrombosis and management- Nick Van Es
12:00 Thrombosis in the context of nephrotic syndrome- Jack Wetzels
12:30 Thrombotic microangiopathy: why do we need a multi-disciplinary management and how long shall we treat?- Meera Sridharan
14:00 Membranous nephropathy- Fernando Fervenza
14:30 Malignancy/tumour-associated nephrotic syndrome- Ladan Zand
15:00 Risk prediction model for AKI prior to initiation of cancer treatment – Laura Cosmai
15:30 COFFEE BREAK
16:00 Toxicity in the aera of CART cells- David Miklos
16:30 Nephrotoxicity of new cancer immunotherapies- Sandra Herrmann
17:00 Closing Remarks & END of the Meeting